These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18833079)

  • 1. Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin.
    Romanelli P; Schlam E; Green JB; Trent JT; Ricotti C; Elgart GW; Kirsner RS; Kerdel FA
    G Ital Dermatol Venereol; 2008 Aug; 143(4):229-33. PubMed ID: 18833079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis.
    Paquet P; Jacob E; Damas P; Pirson J; Piérard G
    Arch Dermatol Res; 2005 Dec; 297(6):266-73. PubMed ID: 16249890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic epidermal necrolysis: review of pathogenesis and management.
    Downey A; Jackson C; Harun N; Cooper A
    J Am Acad Dermatol; 2012 Jun; 66(6):995-1003. PubMed ID: 22169256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
    French LE; Trent JT; Kerdel FA
    Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis.
    Paquet P; Kaveri S; Jacob E; Pirson J; Quatresooz P; Piérard GE
    Exp Dermatol; 2006 May; 15(5):381-6. PubMed ID: 16630079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression.
    Ito K; Hara H; Okada T; Shimojima H; Suzuki H
    Clin Exp Dermatol; 2004 Nov; 29(6):679-80. PubMed ID: 15550154
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits.
    Yip LW; Thong BY; Tan AW; Khin LW; Chng HH; Heng WJ
    Eye (Lond); 2005 Aug; 19(8):846-53. PubMed ID: 15389280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases].
    Molgó M; Carreño N; Hoyos-Bachiloglu R; Andresen M; González S
    Rev Med Chil; 2009 Mar; 137(3):383-9. PubMed ID: 19621180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic epidermal necrolysis and intravenous immunoglobulin: a review.
    Trent J; Halem M; French LE; Kerdel F
    Semin Cutan Med Surg; 2006 Jun; 25(2):91-3. PubMed ID: 16908399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis.
    Al-Mutairi N; Arun J; Osama NE; Amr Z; Mazen AS; Ibtesam el-A; Nazeha el-B
    Int J Dermatol; 2004 Nov; 43(11):847-51. PubMed ID: 15533072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic epidermal necrolysis: current evidence, practical management and future directions.
    Chave TA; Mortimer NJ; Sladden MJ; Hall AP; Hutchinson PE
    Br J Dermatol; 2005 Aug; 153(2):241-53. PubMed ID: 16086734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report.
    Lissia M; Figus A; Rubino C
    Br J Plast Surg; 2005 Jun; 58(4):504-10. PubMed ID: 15897036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.
    Teo L; Tay YK; Liu TT; Kwok C
    Singapore Med J; 2009 Jan; 50(1):29-33. PubMed ID: 19224081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome).
    Paquet P; Piérard GE; Quatresooz P
    Int Arch Allergy Immunol; 2005 Mar; 136(3):205-16. PubMed ID: 15713983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin.
    Sidwell RU; Swift S; Yan CL; Porter W; Thompson EM; Clark JA; Bunker CB
    Int J Clin Pract; 2003 Sep; 57(7):643-5. PubMed ID: 14529073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
    Chen J; Wang B; Zeng Y; Xu H
    Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic epidermal necrolysis (Lyell's disease).
    Lissia M; Mulas P; Bulla A; Rubino C
    Burns; 2010 Mar; 36(2):152-63. PubMed ID: 19766401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.
    Viard I; Wehrli P; Bullani R; Schneider P; Holler N; Salomon D; Hunziker T; Saurat JH; Tschopp J; French LE
    Science; 1998 Oct; 282(5388):490-3. PubMed ID: 9774279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.